{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T09:30:02Z","timestamp":1775381402392,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1124\/jpet.123.001826","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T22:20:18Z","timestamp":1697149218000},"page":"315-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors"],"prefix":"10.1016","volume":"387","author":[{"given":"Wenqiu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Hee","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4631-0085","authenticated-orcid":false,"given":"Sneha","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon D.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Wechsler-Reya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael W.","family":"Sirianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William F.","family":"Elmquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.123.001826_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/jpet.110.167601","article-title":"Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux","volume":"334","author":"Agarwal","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001826_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/jpet.123.001826_bib3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges","volume":"280","author":"Atadja","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1124\/jpet.123.001826_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01062139","article-title":"Testing for the equality of area under the curves when using destructive measurement techniques","volume":"16","author":"Bailer","year":"1988","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/jpet.123.001826_bib5","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4065\/82.10.1271","article-title":"Central nervous system tumors","volume":"82","author":"Buckner","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1124\/jpet.123.001826_bib6","doi-asserted-by":"crossref","first-page":"20960","DOI":"10.1021\/acsami.0c22587","article-title":"\u03b2-Cyclodextrin-poly (\u03b2-Amino Ester) Nanoparticles Are a Generalizable Strategy for High Loading and Sustained Release of HDAC Inhibitors","volume":"13","author":"Chaudhuri","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1124\/jpet.123.001826_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF03160026","article-title":"Regional lipid composition in the rat brain","volume":"18","author":"Chavko","year":"1993","journal-title":"Mol Chem Neuropathol"},{"key":"10.1124\/jpet.123.001826_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3233\/JHD-160226","article-title":"LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington\u2019s Disease","volume":"5","author":"Chopra","year":"2016","journal-title":"J Huntingtons Dis"},{"issue":"Pt A","key":"10.1124\/jpet.123.001826_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2015.10.013","article-title":"A critical evaluation of drug delivery from ligand modified nanoparticles: Confounding small molecule distribution and efficacy in the central nervous system","volume":"220","author":"Cook","year":"2015","journal-title":"J Control Release"},{"key":"10.1124\/jpet.123.001826_bib10","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1124\/jpet.102.045260","article-title":"Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux","volume":"304","author":"Dai","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001826_bib11","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/leu.2013.38","article-title":"Phase Ia\/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies","volume":"27","author":"DeAngelo","year":"2013","journal-title":"Leukemia"},{"key":"10.1124\/jpet.123.001826_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.addr.2020.02.006","article-title":"Intrathecal drug delivery in the era of nanomedicine","volume":"165-166","author":"Fowler","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/jpet.123.001826_bib14","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.cell.2018.01.038","article-title":"A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases","volume":"172","author":"Garzia","year":"2018","journal-title":"Cell"},{"key":"10.1124\/jpet.123.001826_bib15","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","article-title":"Histone deacetylases and cancer","volume":"26","author":"Glozak","year":"2007","journal-title":"Oncogene"},{"key":"10.1124\/jpet.123.001826_bib16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/08880018.2020.1752869","article-title":"A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies","volume":"37","author":"Goldberg","year":"2020","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1124\/jpet.123.001826_bib17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1152\/physrev.00012.2010","article-title":"Epigenetic regulation of gene expression in physiological and pathological brain processes","volume":"91","author":"Gr\u00e4ff","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1124\/jpet.123.001826_bib18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat Med"},{"key":"10.1124\/jpet.123.001826_bib19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40478-020-00953-2","article-title":"Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients","volume":"8","author":"Guntner","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.1124\/jpet.123.001826_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169485","article-title":"Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models","volume":"12","author":"Hennika","year":"2017","journal-title":"PLoS One"},{"key":"10.1124\/jpet.123.001826_bib21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-021-04313-2","article-title":"Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model","volume":"88","author":"Homan","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.123.001826_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85061","article-title":"Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma","volume":"1","author":"Imai","year":"2016","journal-title":"JCI Insight"},{"key":"10.1124\/jpet.123.001826_bib23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","article-title":"The fundamental role of epigenetic events in cancer","volume":"3","author":"Jones","year":"2002","journal-title":"Nat Rev Genet"},{"key":"10.1124\/jpet.123.001826_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","article-title":"Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery","volume":"23","author":"Kalvass","year":"2002","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/jpet.123.001826_bib25","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1124\/jpet.111.180398","volume":"339","author":"Kodaira","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001826_bib26","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1124\/jpet.109.162321","article-title":"Kinetic analysis of the cooperation of P-glycoprotein (P-gp\/Abcb1) and breast cancer resistance protein (Bcrp\/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone","volume":"333","author":"Kodaira","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001826_bib27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.21873\/cgp.20230","article-title":"Normal Mouse Brain Proteome II: Analysis of Brain Regions by High-resolution Mass Spectrometry","volume":"17","author":"Korovesi","year":"2020","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1124\/jpet.123.001826_bib28","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/neuonc\/nou350","article-title":"Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma","volume":"17","author":"Lee","year":"2015","journal-title":"Neuro-oncol"},{"key":"10.1124\/jpet.123.001826_bib29","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1023\/A:1024406221962","article-title":"Modulation of nonspecific binding in ultrafiltration protein binding studies","volume":"20","author":"Lee","year":"2003","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.123.001826_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw0064","article-title":"Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening","volume":"11","author":"Lin","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1124\/jpet.123.001826_bib31","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s11095-022-03246-6","article-title":"Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain-a Game Changing Parameter for CNS Drug Discovery and Development","volume":"39","author":"Loryan","year":"2022","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.123.001826_bib32","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1124\/jpet.123.001826_bib33","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1101\/gad.1232504","article-title":"Epigenetics and cancer","volume":"18","author":"Lund","year":"2004","journal-title":"Genes Dev"},{"key":"10.1124\/jpet.123.001826_bib34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11060-012-0978-1","article-title":"HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment","volume":"110","author":"Milde","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1124\/jpet.123.001826_bib35","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1158\/1078-0432.CCR-10-0395","article-title":"HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth","volume":"16","author":"Milde","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1124\/jpet.123.001826_bib36","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/neuonc\/noac079.067","article-title":"DIPG-10. A Phase I trial of panobinostat following radiation therapy in children with diffuse intrinsic pontine glioma (DIPG) or H3K27M-mutated thalamic diffuse midline glioma (DMG): Report from the Pediatric Brain Tumor Consortium (PBTC-047)","volume":"24","author":"Monje","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1124\/jpet.123.001826_bib37","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1248\/bpb1978.9.819","article-title":"A possible contribution of phospholipids in tissue distribution of quinidine in rats","volume":"9","author":"Nishiura","year":"1986","journal-title":"J Pharmacobiodyn"},{"key":"10.1124\/jpet.123.001826_bib39","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/neuonc\/noz089","article-title":"A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma","volume":"21","author":"Pak","year":"2019","journal-title":"Neuro-oncol"},{"key":"10.1124\/jpet.123.001826_bib40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","article-title":"HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma","volume":"29","author":"Pei","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1124\/jpet.123.001826_bib41","doi-asserted-by":"crossref","first-page":"56747","DOI":"10.18632\/oncotarget.18132","article-title":"Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model","volume":"8","author":"Phi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1124\/jpet.123.001826_bib42","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ccell.2016.03.002","article-title":"Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype","volume":"29","author":"Phoenix","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1124\/jpet.123.001826_bib43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/neuonc\/noq200","article-title":"MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC)","volume":"13","author":"Poussaint","year":"2011","journal-title":"Neuro-oncol"},{"key":"10.1124\/jpet.123.001826_bib44","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1073\/pnas.96.7.3900","article-title":"Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier","volume":"96","author":"Rao","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.123.001826_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv037","article-title":"Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system","volume":"2","author":"Rasmussen","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1124\/jpet.123.001826_bib46","first-page":"55226","article-title":"Hydraulic Extrusion of the Spinal Cord and Isolation of Dorsal Root Ganglia in Rodents","volume":"119","author":"Richner","year":"2017","journal-title":"J Vis Exp"},{"key":"10.1124\/jpet.123.001826_bib47","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1124\/jpet.105.086173","article-title":"Pharmacodynamic and pharmacokinetic studies of agmatine after spinal administration in the mouse","volume":"314","author":"Roberts","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001826_bib48","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00280-019-04021-y","article-title":"Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma","volume":"85","author":"Rodgers","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.123.001826_bib49","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/B978-0-12-380916-2.00008-5","article-title":"Cerebellum development and medulloblastoma","volume":"94","author":"Roussel","year":"2011","journal-title":"Curr Top Dev Biol"},{"key":"10.1124\/jpet.123.001826_bib50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3171\/2020.2.PEDS19786","article-title":"High-dose MTX110 (soluble panobinostat) safely administered into the fourth ventricle in a nonhuman primate model","volume":"26","author":"Sandberg","year":"2020","journal-title":"J Neurosurg Pediatr"},{"key":"10.1124\/jpet.123.001826_bib51","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro-oncol"},{"key":"10.1124\/jpet.123.001826_bib52","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00228-015-1846-7","article-title":"Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors","volume":"71","author":"Savelieva","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/jpet.123.001826_bib53","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1002\/cncr.33080","article-title":"Pediatric cancer mortality and survival in the United States, 2001-2016","volume":"126","author":"Siegel","year":"2020","journal-title":"Cancer"},{"key":"10.1124\/jpet.123.001826_bib54","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2147\/IJN.S125300","article-title":"Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model","volume":"12","author":"Singleton","year":"2017","journal-title":"Int J Nanomedicine"},{"key":"10.1124\/jpet.123.001826_bib55","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3171\/2018.2.PEDS17663","article-title":"The distribution, clearance, and brainstem toxicity of panobinostat administered by convection-enhanced delivery","volume":"22","author":"Singleton","year":"2018","journal-title":"J Neurosurg Pediatr"},{"key":"10.1124\/jpet.123.001826_bib56","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.123.001826_bib57","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0169-409X(02)00172-2","article-title":"Drug efflux transporters in the CNS","volume":"55","author":"Sun","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/jpet.123.001826_bib58","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1124\/jpet.122.001230","article-title":"Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors","volume":"383","author":"Talele","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001826_bib59","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1124\/jpet.121.001069","article-title":"Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain Metastases","volume":"381","author":"Talele","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001826_bib60","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3322\/caac.21613","article-title":"Management of glioblastoma: State of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1124\/jpet.123.001826_bib61","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fonc.2018.00239","article-title":"Beyond the Blood:Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma","volume":"8","author":"Warren","year":"2018","journal-title":"Front Oncol"},{"key":"10.1124\/jpet.123.001826_bib62","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2019.00092","article-title":"Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas","volume":"9","author":"Welby","year":"2019","journal-title":"Front Oncol"},{"key":"10.1124\/jpet.123.001826_bib63","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00280-018-3634-4","article-title":"A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors","volume":"82","author":"Wood","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.123.001826_bib64","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fnana.2017.00128","article-title":"Precise Cerebral Vascular Atlas in Stereotaxic Coordinates of Whole Mouse Brain","volume":"11","author":"Xiong","year":"2017","journal-title":"Front Neuroanat"},{"key":"10.1124\/jpet.123.001826_bib65","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1023\/A:1015935031933","article-title":"Phosphatidylserine as a determinant for the tissue distribution of weakly basic drugs in rats","volume":"7","author":"Yata","year":"1990","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.123.001826_bib66","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/jps.23557","article-title":"Propagation of error in ocular pharmacokinetic parameters estimate of azithromycin in rabbits","volume":"102","author":"You","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.123.001826_bib67","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/jps.2600820718","article-title":"Estimation of variance for AUC in animal studies","volume":"82","author":"Yuan","year":"1993","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.123.001826_bib68","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1158\/1078-0432.CCR-07-0658","article-title":"Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition","volume":"13","author":"Zhou","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524171248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524171248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.123.001826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:32:11Z","timestamp":1739971931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524171248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0022356524171248"],"URL":"https:\/\/doi.org\/10.1124\/jpet.123.001826","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.123.001826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}